Table 4.
Altered pathways (KEGG) in different types of cancer.
| % samples per pathway alteration | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KEGG ID | KEGG pathway | Nb of genes | Glioma (n=33) | Lung (n=27) | Breast (n=25) | Colorectal (n=10) | Prostate (n=10) | Pancreatic (n=8) | Ovarian (n=7) | Head & Neck (n=6) | Gastric (n=5) |
| hsa05200 | Pathways in cancer | 112 | 54,5 | 74,1 | 96,0 | 100,0 | 100,0 | 62,5 | 100,0 | 66,7 | 100,0 |
| hsa04151 | PI3K-Akt signaling pathway | 73 | 51,5 | 66,7 | 88,0 | 100,0 | 60,0 | 62,5 | 100,0 | 66,7 | 100,0 |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance | 38 | 42,4 | 37,0 | 80,0 | 60,0 | 30,0 | 37,5 | 57,1 | 16,7 | 80,0 |
| hsa04010 | MAPK signaling pathway | 54 | 48,5 | 66,7 | 92,0 | 100,0 | 70,0 | 37,5 | 100,0 | 66,7 | 100,0 |
| hsa04012 | ErbB signaling pathway | 30 | 27,3 | 40,7 | 72,0 | 60,0 | 30,0 | 25,0 | 42,9 | 33,3 | 80,0 |
| hsa04014 | Ras signaling pathway | 44 | 39,4 | 33,3 | 88,0 | 70,0 | 20,0 | 25,0 | 57,1 | 33,3 | 80,0 |
| hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 26 | 36,4 | 37,0 | 60,0 | 60,0 | 20,0 | 37,5 | 42,9 | 33,3 | 60,0 |
| hsa04630 | JAK-STAT signaling pathway | 31 | 24,2 | 22,2 | 68,0 | 30,0 | 20,0 | 25,0 | 42,9 | 33,3 | 80,0 |
| hsa04150 | mTOR signaling pathway | 25 | 30,3 | 37,0 | 64,0 | 70,0 | 20,0 | 37,5 | 42,9 | 16,7 | 80,0 |
| hsa04310 | Wnt signaling pathway | 16 | 27,3 | 59,3 | 48,0 | 100,0 | 70,0 | 62,5 | 85,7 | 50,0 | 60,0 |
| hsa04340 | Hedgehog signaling pathway | 9 | 0,0 | 0,0 | 24,0 | 0,0 | 0,0 | 25,0 | 0,0 | 33,3 | 0,0 |
| hsa04330 | Notch signaling pathway | 6 | 3,0 | 0,0 | 4,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 40,0 |
| hsa04064 | NF-kappa B signaling pathway | 11 | 3,0 | 7,4 | 8,0 | 0,0 | 0,0 | 12,5 | 0,0 | 16,7 | 40,0 |
| hsa04722 | Neurotrophin signaling pathway | 27 | 36,4 | 59,3 | 72,0 | 90,0 | 70,0 | 37,5 | 100,0 | 50,0 | 80,0 |
| hsa04390 | Hippo signaling pathway | 18 | 3,0 | 11,1 | 44,0 | 80,0 | 10,0 | 50,0 | 0,0 | 33,3 | 80,0 |
| hsa04115 | p53 signaling pathway | 21 | 42,4 | 51,9 | 60,0 | 80,0 | 70,0 | 62,5 | 85,7 | 66,7 | 80,0 |
| hsa04110 | Cell cycle | 27 | 36,4 | 51,9 | 60,0 | 90,0 | 60,0 | 62,5 | 85,7 | 66,7 | 80,0 |
| hsa04210 | Apoptosis | 27 | 33,3 | 55,6 | 64,0 | 90,0 | 60,0 | 50,0 | 100,0 | 66,7 | 80,0 |
| hsa05202 | Transcriptional misregulation in cancer | 39 | 30,3 | 59,3 | 36,0 | 100,0 | 70,0 | 37,5 | 100,0 | 66,7 | 80,0 |
| hsa03440 | Homologous recombination/alterations in the DNA repair pathway | 16 | 6,1 | 0,0 | 16,0 | 0,0 | 0,0 | 25,0 | 14,3 | 16,7 | 40,0 |
| hsa03430 | Mismatch repair | 6 | 6,1 | 3,7 | 4,0 | 0,0 | 0,0 | 0,0 | 0,0 | 16,7 | 0,0 |
| hsa03410 | Base excision repair | 6 | 6,1 | 3,7 | 12,0 | 0,0 | 0,0 | 0,0 | 14,3 | 0,0 | 0,0 |
| hsa01524 | Platinum drug resistance | 22 | 36,4 | 51,9 | 60,0 | 80,0 | 60,0 | 37,5 | 100,0 | 66,7 | 80,0 |
| hsa04120 | Ubiquitin mediated proteolysis | 12 | 12,1 | 18,5 | 16,0 | 10,0 | 0,0 | 0,0 | 0,0 | 0,0 | 40,0 |
| hsa04140 | Autophagy - animal | 23 | 30,3 | 33,3 | 64,0 | 60,0 | 10,0 | 37,5 | 42,9 | 16,7 | 80,0 |
Cancers for which more than five patients had available sequencing results were analyzed. Pathways associated with 324 genes from the FoundationOne CDx panel were retrieved from the KEGG database using the DAVID (Database for Annotation, Visualization and Integrated Discovery) enrichment tool. The percentage of patients with 4-5 alterations in at least one gene belonging to a KEGG pathway are indicated in a yellow-to-red gradient (yellow = <30%; orange = ≥30% and <50%; and red = ≥ 50%).